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EDITORIAL
Year’s comments for 2005
For several years, new sequences of microbial genomes have
been the highlights of microbiology and a major topic of our
yearly comments. But sequencing has become “routine” and, at
the time this editorial is being written, the complete sequences
of 284 prokaryotic genomes and 40 eukaryotic genomes have
been published. This allows us to focus our comments on those
events from 2005 that have attracted the attention of both
researchers and the media. These include the Nobel Prize in
Physiology or Medicine, which was awarded for the discovery
of the role of Helicobacter pylori as the causal agent of gastric
ulcers; the worldwide effort to fight malaria, a disease that main-
ly affects developing countries; and the global spread of avian
influenza, which is becoming a panzootic.
The 2005 Nobel Prize in Physiology or Medicine was awarded
to a discovery in the field of bacteriology that was made in 1982,
when J. Robin Warren and Barry J. Marshall first observed the
presence of Helicobacter pylori (then Campylobacter pylori) in
the human stomach and related it to subsequent gastritis and
peptic ulcers [3]. Warren and Marshall provided evidence that
the presence of H. pylori in the stomach was always associated
with an inflammation of the underlying gastric mucosa. For the
medical community, recognizing that H. pylori caused ulcer
meant a major paradigm shift: such a disease could no longer be
considered to be psychosomatic; instead, it would enter the
realm of infectious disease [4]. Throughout the century-long his-
tory of the Nobel Prize in Physiology or Medicine, about 21
works related to microbiology have received awards (Table 1).
Pathologists noted the presence of spiral bacteria in the
human stomach as early as 1906. Although similar observations
were repeatedly reported during subsequent decades, they did
not receive much attention because the bacteria could not be cul-
tured. Also, it was long believed that the normal human stomach
was sterile, as a consequence of the extremely low pH of gastric
acid. Cultivation of a novel bacterium from the gastric mucosa,
in 1982, marked a turning point in our understanding of gas-
trointestinal microbial ecology and disease. Marshall and
Warren described spiral or curved bacilli in histological sections.
Moreover, the bacteria were often seen in malignant or ulcerat-
ed gastric tissue. However, the idea that bacteria, and not stress
or acid, were the cause of ulcers flew in the face of medical
dogma. Conclusive evidence for a pathogenic role of H. pylori
came from trials showing that elimination of the bacterium dra-
matically changed the clinical course of ulcer. This finding was
confirmed by Marshall, who swallowed a broth of H. pylori and
soon thereafter developed gastritis, the prelude to ulcers. He
recovered from the disease after treatment with antibiotics.
(Warren could not join him in the experiment because he already
suffered from peptic ulcer.) Subsequently, the two investigators
successfully treated other people suffering from ulcers, in the
process clearly identifying the bacterium as the culprit. In 1994,
H. pylori was the first bacterium, and the second infectious
organism after hepatitis B virus, to be classified as a class I car-
cinogen according to the World Health Organization (WHO) cri-
teria. [As a historical curiosity, note that the 1926 Nobel Prize
(Table 1) was awarded for the discovery of a nematode (a worm)
that “was carcinogenic”.]
Like other bacteria specialized to live in a single environment,
H. pylori has a small genome. H. pylori strain 26695, the first to be
sequenced (in 1997) has a circular chromosome of 1.66 Mb. A sec-
ond complete genome sequence (strain j99) of 1.64 Mb was pub-
lished in 1999. The apparent lack of recombination/repair genes in
the Helicobacter genome offers a plausible explanation for its high
rate of mutation. Nevertheless, the reasons why H. pylori integrates
very small pieces of foreign DNA into its chromosome are current-
ly unknown. The bacterium was thought originally to be a mem-
ber of the genus Campylobacter and was named Campylobacter
pyloridis, later corrected to Campylobacter pylori and finally
Helicobacter pylori (the new genus Helicobacter was estab-
lished in 1989). It is classified in the epsilon subdivision of the
proteobacteria on the basis of its 16S rRNA. There are more than
20 Helicobacter species that colonize both the gastric mucosa
and the intestinal tract and/or the liver (enterohepatic) of humans
and other mammals, such as the human enteric pathogens H.
fennelliae, and H. cinaedi. Bile-resistant organisms were first
isolated from the biliary tract and liver of rodents (H. hepaticus,
H. bilis), while another Helicobacter species (H. felis) is known
to infect cats (Fig. 1). 
Helicobacter pylori has been found in the stomachs of
humans in all parts of the world (and is commonly isolated from
nonhumans as well). In developing countries, 70 to 90% of the
population carries H. pylori, while in developed countries the
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prevalence of infection is lower, ranging from 25 to 50%. The
ability to colonize and persist in the human stomach for many
years indicates that H. pylori is specifically adapted to occupy
only this niche, and such adaptation should be reflected in a
unique complement of physiological capabilities. Although it is
difficult to estimate the requirements for life-long colonization
of the human stomach, H. pylori is clearly confronted with mul-
tiple environmental challenges, such as initial colonization,
adherence, resistance to gastric clearance, protection against the
host immune system, and transmission to another human indi-
vidual with a different genetic background.
Possible symbiotic relationships have been debated since the
discovery of this pathogen, and the debate has been further
intensified by recent studies posing the intriguing possibility that
H. pylori infection may be advantageous in some humans. This
suggestion is based on the increased incidence of several dis-
eases, such as gastro-esophageal reflux disease (GERD),
Barrett’s esophagus, and adenocarcinoma of the esophagus, fol-
lowing H. pylori eradication in some patients.
The cover story of the November 7, 2005 issue of Time maga-
zine was devoted to the fight against diseases that affect devel-
oping countries. The magazine highlighted the work carried out
by a group of 18 “solidarity heroes”, as Time called them, made
up of physicians, researchers, and non-governmental organiza-
tions. Among these heroes is Pedro Alonso, director of the
International Health Center of the Hospital Clínic of the Univer-
sity of Barcelona. Alonso leads a research team that has focused
its work on the development of a vaccine against malaria, a dis-
ease that annually kills 1.5–2.7 million people worldwide.
Ninety percent of malaria’s victims are African children less
than five years old; and in some African regions almost half of
all malaria cases occur in infants less than one year old.
Expectations regarding the candidate vaccine currently being
tested (RTS.S/AS02A) are quite high. A follow-up of 1442 chil-
dren who were inoculated in 2003 has shown that the vaccine
has retained its efficiency over a 1.5-year period. The
RTS.S/AS02A vaccine reduced clinical malaria in 35% of vac-
cinated individuals, and the severe malaria in 49%. These
results, published recently in The Lancet and presented at the
Multilateral Initiative on Malaria’s Pan-African Malaria
Conference, held in Yaounde, Cameroon, in November 2005,
are very promising. The vaccination project is a joint venture of
the International Health Center in Barcelona, GlaxoSmithKline
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Table 1. Main Nobel Prizes in Physiology or Medicine related to microbiology 
Year Scientists Work Field*
1901
1902
1905
1907
1908
1919
1926
1927
1928
1939
1945
1951
1952
1954
1960
1966
1972
1975
1976
1997
2005
Emil von Behring
Ronald Ross
Robert Koch
Alphonse Laveran
Paul Ehrlich, Ilya Mechnikov
Jules Bordet
Johannes Fibiger
Julius Wagner-Jauregg
Charles Nicolle
Gerhard Domagk
Ernst B. Chain, Alexander
Fleming, Howard Florey
Max Theiler
Selman A. Waksman
John F. Enders, Frederick C.
Robbins, Thomas H. Weller
Frank Macfarlane Burnet,
Peter Medawar
Peyton Rous
[Charles B. Huggins]
Gerald M. Edelman,
Rodney R. Porter
David Baltimore, Renato
Dulbecco, Howard M. Temin
Baruch S. Blumberg, 
D. Carleton Gajdusek
Stanley B. Prusiner
Barry J. Marshall,
J. Robin Warren
For his work on serum therapy, especially its application against diphtheria
For his work on malaria showing how the parasite enters the host
For his investigations and discoveries in relation to tuberculosis
In recognition of his work on the role played by protozoa in causing diseases
In recognition of their work on immunity
For his discoveries related to immunity
For his discovery of the Spiroptera carcinoma [a nematode “causing cancer”]
For his discovery of the therapeutic value of malaria inoculation in the treatment of dementia paralytica
For his work on typhus
For the discovery of the antibacterial effects of prontosil
For the discovery of penicillin and its curative effect in various infectious diseases
For his discoveries concerning yellow fever and how to combat it
For his discovery of streptomycin, the first antibiotic effective against tuberculosis
For their discovery of the ability of poliomyelitis viruses to grow in cultures of various types of tissue
For their discovery of acquired immunological tolerance
For his discovery of tumor-inducing viruses
[For his discoveries concerning hormonal treatment of prostatic cancer]
For their discoveries concerning the chemical structure of antibodies
For their discoveries concerning the interaction between tumor viruses and the genetic material of the cell
For their discoveries concerning new mechanisms for the origin and dissemination of infectious diseases
For his discovery of prions, a new biological principle of infection
For their discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease
I
P
B
P
I
I
P
P
B
A
A
V
A
V
I
V
I
V
B-V
V
B
Adapted from: The Nobel Foundation [nobelprize.org/medicine/laureates/index.html].
*Field (or related to): A, antibiotics; B, bacteriology; I, immunology; P, protistology, or parasitology; V, virology.
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(GSK) Biologicals, and the Center for Health Research in
Manhiça, Mozambique, and has received funds from the Bill &
Melinda Gates Foundation.
Another initiative is The International Preventive Treatment
in Infants (IPTi) Consortium [http://ipti-malaria.org], which
evaluates new studies on malaria control in infants and coordi-
nates research on malaria carried out by centers in Africa,
Europe, and the United States, as well as by WHO and the
United Nations Children’s Fund (UNICEF). The IPTi Con-
sortium, also sponsored by the Bill & Melinda Gates
Foundation, has set up its Secretariat at the International Health
Center in Barcelona, and Andrea Egan has been appointed as
Coordinator. Egan is a British scientist with extensive expe-
rience in malaria research, carried out in the UK, Gambia, the
USA and Mali. On the way towards the development of an effec-
tive malaria vaccine, intermittent preventive treatment is a novel
promising strategy to control malaria. Children receiving anti-
malarial drugs intermittently during their first year of life have
half the risk of contracting the disease and of developing infan-
tile anemia. As children are usually the group at highest risk of
disease and death, targeting them is an effective way to control
the disease. By coordinating research and treatment strategies,
the Consortium is also able to standardize approaches to the
measurement of outcome. It can also conduct trials designed
with the same objective and at many sites, which is essential
because the pattern of malaria can vary greatly between geo-
graphic regions.
A recurring microbiological topic during 2005 has been the
widespread outbreaks of avian influenza, or “bird flu”, through-
out southeastern Asia. Like other influenza viruses, avian
influenza viruses are segmented genome RNA viruses belonging
to the family Orthomyxoviridae. The current epizootic, which
began in 2004, is caused by a H5N1 virus (H and N stand for the
hemagglutinin and neuraminidase surface antigens), and there is
tremendous concern that, although such viruses tend to be high-
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ly species-specific, H5N1 will eventually cross the species bar-
rier to infect humans. More than 100 human cases of avian
influenza have been reported during the current outbreaks.
Nevertheless, this is a small number compared with the millions
of birds that have been affected and the many occasions of
human exposure. However, simultaneous infection of humans
(or swine) by avian influenza and human influenza virus could
occur, and the inevitable reassortment of genome subunits
between the two viruses could result in a highly virulent, novel
influenza virus with pandemic potential [2].
On April 28, 2005, the European Commission adopted a pro-
posal for a Directive establishing updated EU-level measures on
the control of avian influenza. Widely updated information on
both the outbreak of avian influenza in Europe and the measures
adopted by the EU can be found at the “Animal Health Welfare”
website of the European Commission: [http://europa.eu.int/comm/
food/animal/diseases/controlmeasures/avian/index_en.htm]. WHO
also has a website providing information about avian influenza,
including a description of the disease; its diagnosis and treat-
ment; surveillance; infection control; food safety; and WHO
guidance on public health measures in countries experiencing
initial outbreaks of H5N1 avian influenza: [http://www.who.int
/csr/disease/avian_influenza/ en/].
* * *
The relationship between the Spanish Society for Microbiology
(SEM) and the American Society for Microbiology (ASM) con-
tinues to grow. The SEM has mediated agreements between the
ASM International Committee and Spanish universities and
research centers to launch a program of scholarships for young
Latin American researchers to train in Spanish laboratories. The
ASM has supported microbiology education and research inter-
nationally since the 1970s, promoting partnerships between
North American microbiologists and foreign scientists and stu-
dents. It also provides training in several related fields, collabo-
Fig. 1. (A) Scanning electron
micrograph of Helicobacter felis
isolated from the gastric mucosa
of a cat. The characteristic spiral
morphology and periplasmic fibers
are shown.  (B) Scanning electron
micrograph of H. pylori from hu-
man gastric epithelium. The gently
curved morphology, multiple polar
flagella, and absence of periplasmic
fibers are shown.  Micrographs cour-
tesy of Lucinda Thompson, pre-
sently at Stanford University, USA.
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rating with international organizations, including the Pan
American Health Organization (PAHO), the United Nations
Educational, Scientific and Cultural Organization (UNESCO),
the International Union of Microbiological Societies (IUMS),
and microbiological societies from all over the world. In Spain,
the ASM has already signed two agreements, one with the
University of Salamanca and the other with the University of the
Balearic Islands. To discuss these developments as well as other
aspects of the relationship between the ASM and the SEM,
Stanley Maloy, current ASM President, and Lily Schuermann,
ASM Director of International Affairs, came to Spain on the
occasion of the 20th Conference of the SEM (Cáceres, Sept.
19–23, 2005). Maloy talked about “The future of microbiology:
An international partnership.” Back in the United States, he
wrote to us about their (his and Schuermann’s) visit to Spain:
“We thoroughly enjoyed hearing the excellent microbiology pre-
sented at the meeting, making many new scientific friends, and
learning more about how the ASM might enhance collaborations
with Spanish microbiologists, […] I was particularly impressed
with the outstanding quality of the young microbiologists partic-
ipating in the meeting, and I thoroughly enjoyed learning about
your science.”
INTERNATIONAL MICROBIOLOGY readers are aware of the journal’s
commitment to open access publication [1]. This has been our
policy even before the term “open access” was coined. For a
non-first-rank journal, however, open access is a double-edged
sword: whereas it makes it possible to increase the journal’s
readership, open access encourages many would-be scientific
authors to submit their articles to the journal. An analysis by
country of both the visits to our website and the origin of articles
submitted to INTERNATIONAL MICROBIOLOGY shows that the num-
ber of articles, especially from scientists in several non-English-
speaking countries, has greatly increased. These figures also tell
much about the increasing visibility of the journal. Most identi-
fied visits over the period January–November 2005 were from
Spain (25.7%), followed by the United States (15%), India
(5.7%), Mexico (4.9%), the United Kingdom (3.6%), and
Germany (3.4%). Google has been the search engine most wide-
ly used to reach the INTERNATIONAL MICROBIOLOGY website.
From November 2004 to November 2005, 112 ‘articles’
(research articles, reviews and research notes) were submitted
for publication to INTERNATIONAL MICROBIOLOGY, of which 29
(25.9%) were published. While this implies a rejection rate higher
than in 2004, it is a result of the considerable increase in the
number of articles received rather than a decrease in the quality
of the articles submitted. The total number of articles published,
including ‘complements’ (editorials, perspectives, and obituar-
ies), was 44. On the occasion of the 13th International Biodete-
rioration and Biodegradation Symposium, held in Madrid in
Sept. 4–9, 2005, the September issue was published as a mono-
graph that included outstanding contributions to the meeting.
The Directory of Open Access Journals (DOAJ), which
includes in its databases only journals that are completely open
access (those that have an embargo period are excluded), com-
prises 22 journals whose subject is microbiology. None of these
is among the journals with the highest impact factors, although
this is, at least in part, due to the fact that several of them are
rather specialized (immunology, filaria, antimicrobials,
halophiles, mycology, pathogens, etc.). However, the impact of
many open-access journals will surely increase in the future, for
two reasons: (i) A growing number of funding agencies are
requiring that articles describing agency-funded research be
published in open-access journals, and (ii) that the journals
where those articles are published must fulfill several require-
ments regarding quality. A recent order of the Spanish Ministry
of Education and Science [BOE, 7 Nov. 2005, pp. 36470–6] on
the evaluation of research included the criteria for a means of
diffusion (journal, book, conference) to be recognized as being
of minimum impact for what is published in it. Those criteria
were based on: (i) the informative quality of the journal as a
means of scientific dissemination; (ii) the quality of the editori-
al process; and (iii) the scientific quality of the journals them-
selves. Our journal satisfy all these criteria.
The number of journals covered in the ISI citation databases
that have switched to an open-access distribution model is
increasing, and new open-access journals have been added to the
ISI databases. In October 2004, the largest numbers of open-
access journals indexed by ISI were in medicine and life sci-
ences. However, it was in the fields of physics, engineering, and
mathematics that open-access journals were more frequent
among the highest ranking journals in their categories [5]. 
Joining the open access initiative comes at a cost that not all
journals can afford. If readers no longer pay the cost of publish-
ing, other ways to cover expenses must be sought. The generos-
ity of institutions and centers that pay for subscriptions to the
journal—despite the on-line availability, at no charge, of the
entire contents of the journal—and the participation of an edito-
rial team devoted to the journal as if it were an all-volunteer,
‘non-governmental organization’, make possible the publication
of INTERNATIONAL MICROBIOLOGY and its contribution to pro-
moting microbiology in Spain, Portugal and Latin America, and
expanding microbiological knowledge worldwide.
References
1. Guerrero R, Piqueras M (2004) Open access: A turning point in scien-
tific publication. Int Microbiol 7:157-161
2. Kaye D, Pringle CR (2005) Avian influenza viruses and their implica-
tion for human health. Clin Infect Dis 40:108-112
3. Marshall BJ, Royce H, Annear DI, Goodwin CS, Pearman JW, Warren
J, Armstrong JA (1984) Original isolation of Campylobacter pylori from
human gastric mucosa. Microbios Lett 25:83–88
4. Marshall BJ (1995) The Lasker awards: Celebrating scientific discover-
ies. JAMA 294:1420-1422
5. Mc Veigh ME (2004) Open access journals in the ISI citation databases:
Analysis of impact factors and citation patterns. A citation study from
Thomson Scientific. Available at:  <http://scientific.thomson.com
/media/presentrep/essayspdf/openaccesscitations2.pdf> [visited on
November 16, 2005]
